Literature DB >> 31449489

Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapy.

Amina Nardo-Marino1, Katrine Bukan1,2, Henrik Vedel Nielsen3, Daniel El Fassi1,4.   

Abstract

Entities:  

Year:  2019        PMID： 31449489      PMCID： PMC6812896          DOI： 10.5152/eurjrheum.2019.18178

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN： 2147-9720


× No keyword cloud information.
  6 in total

Review 1.  Visceral leishmaniasis and anti-TNF-alpha therapy: case report and review of the literature.

Authors:  F De Leonardis; M Govoni; A Lo Monaco; F Trotta
Journal:  Clin Exp Rheumatol       Date:  2009 May-Jun       Impact factor: 4.473

2.  Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy.

Authors:  K B Bukan; A Nardo-Marino; C Hagdrup; M Boennelycke; M F Breinholdt; C Schöllkopf; H V Nielsen; D El Fassi
Journal:  Scand J Rheumatol       Date:  2018-12-10       Impact factor: 3.641

3.  Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis.

Authors:  Göksel Güven; Aslıhan Güler; Nil Özyüncü; Leyla Talan; Aylin Heper; Tahsin Murat Turgay; Neriman Defne Altıntaş
Journal:  Eur J Rheumatol       Date:  2018-02-13

4.  Hemophagocytic lymphohistiocytosis in imported pediatric visceral leishmaniasis in a nonendemic area.

Authors:  Sebastian F N Bode; Christian Bogdan; Karin Beutel; Wolfgang Behnisch; Jeanette Greiner; Stephan Henning; Norbert Jorch; Martin Jankofsky; Marcus Jakob; Irene Schmid; Norbert Veelken; Thomas Vraetz; Gritta Janka; Stephan Ehl; Kai Lehmberg
Journal:  J Pediatr       Date:  2014-05-03       Impact factor: 4.406

Review 5.  Adult haemophagocytic syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Armando López-Guillermo; Munther A Khamashta; Xavier Bosch
Journal:  Lancet       Date:  2013-11-27       Impact factor: 79.321

6.  Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, london.

Authors:  Kate Fletcher; Rita Issa; D N J Lockwood
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.